Healthcare Industry News: tyrosine kinase inhibitor
News Release - November 7, 2006
Cleveland Clinic Unveils 'Top 10' Medical Innovations for 2007Ten Emerging Technologies Will Shape Healthcare Next Year, Hospital Predicts
CLEVELAND, Nov. 7 (HSMN NewsFeed) -- Cleveland Clinic today announced its first-ever Top 10 Medical Innovations list, highlighting technologies which will likely have a big impact on healthcare in 2007.
The list of up-and-coming devices and therapies was selected by a panel of Cleveland Clinic physicians and scientists and was unveiled during Cleveland Clinic's 2006 Medical Innovation Summit, which is currently underway. They include therapies for cancer, asthma, heart failure, age-related macular degeneration and vascular disease.
"The use of state of the art technology and their leading role in evaluating next generation products has long characterized Cleveland Clinic physicians. Their passion for getting the best care for patients drives a continuous dialogue on what technologies are just over the horizon," said Christopher Coburn, Executive Director of CCF Innovations, Cleveland Clinic's technology commercialization arm. "The Top 10 is a result of a survey of dozens of Cleveland Clinic thought leaders offered to promote widespread discussion on innovation and new technology."
The Top 10 Medical Innovations for 2007 are:
10. Convection-enhanced delivery (CED) of drugs: This emerging drug delivery method is being used to administer medication directly to the site where it is needed, without exposing the rest of the body to a drug's effects.
9. Left Ventricular Assist System (LVAS): This is the first implanted ventricular assist device (VAD) that senses when to increase or decrease the rate of blood flow. The device takes over most of the function of the left ventricle, the heart's main pumping chamber, and helps generate the force necessary to propel oxygen-rich blood throughout the body.
8. Targeted cancer therapies: Using second generation, small molecule tyrosine kinase inhibitors to block or modulate disease and provide treatments for advanced cancers, such as renal cell carcinoma (RCC). Clear cell carcinoma is the most common type of kidney cancer which represents 2 percent of all adult cancers.
7. Endografting: This is a minimally invasive repair technique traditionally used in cardiology and now being used to treat vascular disease, such as thoracic abdominal aneurysms.
6. Ranibizumab: This drug therapy inhibits uncontrolled blood vessel formation in the eye, which is the primary cause of age-related macular degeneration, the leading cause of new blindness in older Americans.
5. Bronchial Thermoplasty (BT): This therapy is used to ward off asthma attacks. BT involves the controlled application of heat in the lungs to improve pulmonary function and reduce asthma symptoms. Approximately 20 million Americans suffer from asthma, according to the American Lung Association.
4. OCT (optical coherence tomography): This is a noninvasive imaging technology used in the treatment and diagnosis of eye diseases, such as diabetic retinopathy and macular holes.
3. Neurostimulation for Psychiatric Disorders: Neurostimulation, such as Deep Brain Stimulation (DBS), is emerging as a significant treatment option for millions of Americans who are suffering from Treatment Resistant Depression and Treatment Resistant Obsessive Compulsive Disorder.
2. Designer Therapeutics Using Selective Receptor Antagonists: Creating therapeutics to block receptor activation that leads to improved patients' outcomes. Examples include therapeutics that: block the peripheral side effects, such as constipation and nausea, of opioid medications for pain which can adversely affect patients and lengthen hospitalizations; control the body's stress response to mediate eating and smoking; increase good cholesterol using niacin.
1. Cancer Vaccines: These targeted therapies are being used to prevent cancer and treat patients more specifically according to the type of cancer they have. One example of a cancer vaccine is the HPV vaccine developed to prevent cervical cancer caused by human papillomaviruses.
Marc Penn, M.D., Ph.D., Chair of the Bakken Heart Brain Institute, chaired the project and moderated the panel at the Summit. "2007 will be an exciting year for the introduction of new technologies in healthcare," said Penn. "For patients and healthcare providers, the Top 10 list is an example of significant technologies that will help to fight many conditions for which there have been limited or non-existent treatment options."
Four major criteria served as the basis for qualifying and selecting the Top 10 innovations. To receive consideration, a nominated innovation was required to:
* Have significant potential for short-term clinical impact (either a major improvement in patient benefit or an improved function that enhances healthcare delivery).
* Have a high probability of success.
* Be on the market or close to being introduced.
* Have sufficient data available to support its nomination.
The Top 10 Medical Innovations for 2007 were announced Nov. 7 at the 2006 Cleveland Clinic Medical Innovation Summit. A panel of eight Cleveland Clinic thought leaders and a moderator discussed each technology and its reason for inclusion during a panel session.
In developing the Top 10, Cleveland Clinic enlisted the expertise of AlixPartners, LLC, an independent international management consulting firm. AlixPartners led the process to probe the opinions of Cleveland Clinic physicians and researchers, create a field of nominated innovative technologies for consideration, and develop a consensus perspective on what will be the Top 10 for 2007.
For more information about the 2006 Medical Innovation Summit and the conference agenda, visit http://www.clevelandclinic.org/innovations.
CCF Innovations, the technology commercialization arm of Cleveland Clinic, organizes the Medical Innovation Summit and stewards the Clinic's technology innovation strategy. It enhances product-oriented innovation throughout Cleveland Clinic and transforms promising therapies, devices and diagnostics into beneficial medical products, via spin-off companies, licensees and equity partnerships.
Cleveland Clinic, located in Cleveland, Ohio, is a not-for-profit multispecialty academic medical center that integrates clinical and hospital care with research and education. Cleveland Clinic was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. U.S. News & World Report consistently names Cleveland Clinic as one of the nation's best hospitals in its annual "America's Best Hospitals" survey. Approximately 1,500 full-time salaried physicians at Cleveland Clinic and Cleveland Clinic Florida represent more than 100 medical specialties and subspecialties. In 2005, there were 2.9 million outpatient visits to Cleveland Clinic. Patients came for treatment from every state and from more than 80 countries. There were nearly 54,000 hospital admissions to Cleveland Clinic in 2005. Cleveland Clinic's Web site address is http://www.clevelandclinic.org.
Source: Cleveland Clinic
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.